Cardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor

Dutton, Luke C.; Dudhia, Jayesh; Catchpole, Briän; Hodgkiss-Geere, Hannah; Werling, Dirk; Connolly, David

doi:10.1038/s41598-018-31569-1

Cited by 11 publications

(9 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CDCs are a group of CPCs that have the ability to motivate endogenous mechanisms of cardiac repair and attenuate adverse ventricular remodeling 100 , and also have been proven to improve cardiac function in a variety of heart diseases 101 . CDC-derived exosomes (CDC-Exos) could also mitigate the myocardium damage caused by AMI, having the ability to relieve oxidative stress, reduce cell apoptosis and adverse ventricular remodeling, and facilitate angiogenesis after MI 102 - 105 .…”

Section: Immune Cell-derived Exosomes In Immunomodulation After Amimentioning

confidence: 99%

The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction

Xiong¹,

Gong²,

Tang³

et al. 2021

Theranostics

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is one of the leading causes of mortality around the world, and the inflammatory response plays a pivotal role in the progress of myocardial necrosis and ventricular remodeling, dysfunction and heart failure after AMI. Therapies aimed at modulating immune response after AMI on a molecular and cellular basis are urgently needed. Exosomes are a type of extracellular vesicles which contain a large amount of biologically active substances, like lipids, nucleic acids, proteins and so on. Emerging evidence suggests key roles of exosomes in immune regulation post AMI. A variety of immune cells participate in the immunomodulation after AMI, working together to clean up necrotic tissue and repair damaged myocardium. Stem cell therapy for myocardial infarction has long been a research hotspot during the last two decades and exosomes secreted by stem cells are important active substances and have similar therapeutic effects of immunomodulation, anti-apoptosis, anti-fibrotic and angiogenesis to those of stem cells themselves. Therefore, in this review, we focus on the characteristics and roles of exosomes produced by both of endogenous immune cells and exogenous stem cells in myocardial repair through immunomodulation after AMI.

show abstract

Section: Immune Cell-derived Exosomes In Immunomodulation After Amimentioning

confidence: 99%

The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction

Xiong¹,

Gong²,

Tang³

et al. 2021

Theranostics

View full text Add to dashboard Cite

show abstract

“…However we have demonstrated that cryopreservation of dog CDCs does not alter their immunophenotype and cellular characteristics (Dutton et al, 2018a). Furthermore, we have shown at a molecular level that canine CDCs are also immune-privileged similar to the immunomodulatory function of MSCs (Dutton et al, 2018b) and cryopreservation retains this property suggesting they are safe to use in vivo.…”

Section: Human and Canine Dilated And Arrhythmogenic Ventricular Cardmentioning

confidence: 78%

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

Ribitsch

Baptista

Consiglio

et al. 2020

Front. Bioeng. Biotechnol.

Self Cite

158

110

View full text Add to dashboard Cite

Rapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress

show abstract

“…Cardiosphere derived cells (CDCs) are cardiac progenitor cells, which can regenerate heart tissue and be used in several cardiac diseases [63]. Given that SARS-CoV-2 can attack cardiac cells and lead to serious cardiovascular complications [42], the application of CAP-1002 can be considered as a candidate treatment in these patients.…”

Section: Allogeneic Cardiosphere-derived Cells (Cap-1002)mentioning

confidence: 99%

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment

Basiri

Mansouri

Azari

et al. 2021

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Currently, there are no specific and efficient vaccines or drugs for COVID-19, particularly in severe cases. A wide range of variations in the clinical symptoms of different patients attributed to genomic differences. Therefore, personalized treatments seem to play a critical role in improving these symptoms and even similar conditions. Prompted by the uncertainties in the area of COVID-19 therapies, we reviewed the published papers and concepts to gather and provide useful information to clinicians and researchers interested in personalized medicine and cell-based therapy. One novel aspect of this study focuses on the potential application of personalized medicine in treating severe cases of COVID-19. However, it is theoretical, as any real-world examples of the use of genuinely personalized medicine have not existed yet. Nevertheless, we know that stem cells, especially MSCs, have immune-modulatory effects and can be stored for future personalized medicine applications. This theory has been conjugated with some evidence that we review in the present study. Besides, we discuss the importance of personalized medicine and its possible aspects in COVID-19 treatment, then review the cell-based therapy studies for COVID-19 with a particular focus on stem cell-based therapies as a primary personalized tool medicine. However, the idea of cell-based therapy has not been accepted by several scientific communities due to some concerns of lack of satisfactory clinical studies; still, the MSCs and their clinical outcomes have been revealed the safety and potency of this therapeutic approach in several diseases, especially in the immune-mediated inflammatory diseases and some incurable diseases. Promising outcomes have resulted in that clinical studies are going to continue.

show abstract

Cardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor

Cited by 11 publications

References 72 publications

The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction

The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment

Contact Info

Product

Resources

About